Business
Facebook Survey Shows UK Consumers Experience 52% Reduction in Intractable Chronic Pain with ActiPatch® Therapy in Musculoskeletal Pain
Facebook Survey Shows UK Consumers Experience 52% Reduction in Intractable Chronic Pain with ActiPatch® Therapy in Musculoskeletal Pain.
About this update from Bioelectronics Corp.
[{"type":"text","content":"\n\n\n\nFacebook Survey Shows UK Consumers Experience 52% Reduction in Intractable Chronic Pain with ActiPatch® Therapy in Musculoskeletal Pain\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nFacebook Survey Shows UK Consumers Experience 52% Reduction in Intractable Chronic Pain with ActiPatch® Therapy in Musculoskeletal Pain\nPR Newswire\nFREDERICK, Md., Aug. 26, 2014\n\n\n\nFREDERICK, Md., Aug. 26, 2014 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced drug-free consumer medical devices, today released the updated results of its \"Try It and Tell Us\" 7-day ActiPatch sample program for United Kingdom and Ireland residents who were surveyed about their experience. Overall results for chronic musculoskeletal pain showed a 77% efficacy to ActiPatch Therapy with an average pain decrease of 52%. Visit www.bielcorp.com/clinical-evidence/musculoskeletal-pain to see the 430 consumer responses and www.facebook.com/ActiPatch to view what people in the UK and Ireland are saying about the products. \n\n\"These consistent results across varied disease states establish two critical facts,\" said Ian Rawe, Ph.D., Director of Clinical Research at BioElectronics Corporation.  \"ActiPatch Therapy works on the fundamental problem of inflammation and pain and it is meeting a critical unmet need in chronic pain management.\"\n\nSpecific disease condition results were:\n\n\nChronic Back Pain sufferers reported 76% efficacy to ActiPatch Therapy with a 50% improvement in average pain levels. \nOsteoarthritis sufferers have a higher baseline pain average and 85% of them reported efficacy to ActiPatch Therapy with a pain level drop of 52% \nFibromyalgia sufferers; 75% efficacy to ActiPatch Therapy with a 49 % decrease in pain. \nRheumatoid Arthritis sufferers; reported 83% efficacy to ActiPatch Therapy with a 52% average drop in pain. \nPost-Surgery Chronic Pain sufferers; 66% efficacy to ActiPatch, Therapy with a 52% decrease in pain. \nNeuropathy sufferers; 64% efficacy to ActiPatch, Therapy with a 51% decrease in pain. ...